Abstract
Thirty-four patients with accelerated hypertension were clinically examined. The visual evoked potential (VEP) and electroretinogram (ERG) were recorded: acutely in 12 patients, being repeated in 7 patients up to 6 months later. In the remaining 22 patients these tests were performed 2-4 years after presentation. Visual acuity was ≤6/12 in 22 of 68 (32%) eyes at presentation and ≤6/12 in 10 of 58 (19%) eyes at follow-up. The cause of severest loss of vision appeared to be anterior ischaemic optic neuropathy, found in 3 cases. During the acute stage 11 patients (92%) had abnormal VEPs and all had abnormal ERGs. The group mean P100 latency, of the 7 patients (14 eyes) seen acutely and followed up at 6 months, was 123.8 ms with significant recovery of latency (p<0.005) to 110.9 ms. The ERGs, however, remained reduced and delayed. In those patients recorded 2-4 years after their acute episode the VEP was abnormal in only 2 patients (9%); group mean P100 latency was 109.1 ms. However, 18 patients (82%) had abnormal ERGs. We suggest that during the acute stage of accelerated hyertension there is a high incidence of ischaemic optic neuropathy that usually resolves but can cause a permanent anterior ischaemic optic neuropathy, in addition to vascular retinopathy that persists.
Similar content being viewed by others
Article PDF
References
Bright R . Cases and observations, illustrative of renal disease accompanied with the secretion of albuminous urine. Guys Hosp Rep 1836;1:338–400.
Mackenzie. Amaurosis from fatty degeneration of the retina, originating in Bright's disease. R Lond Ophthalmic Hosp Rep 1860;2:181–5.
Duke-Elder WS, (ed). Textbook of ophthalmology, vol III. London: H. Kimpton, 1940;2676.
Leibreich R . Ophthalmoskopischer Bejund bin Morbus Brightii. Graefes Arch Clin Exp Ophthalmol 1859;5:265–8.
Riva-Rocci S . Gazz med di Torino 1896;47:981.Gazz med di Torino 1896;47:981.
Volhard F, Fahr KT . Die Brightsche Nierenkrankheit; Klinik, Pathologie und Atlas. Berlin: Springer, 1914.
Keith NM, Wagener HP, Barker NW . Some different types of essential hypertension: their course and prognosis. Am J Med Sci 1939;197:332–43.
Bulpitt CJ . Prognosis of treated hypertension 1951– 1981. Br J Clin Pharmacol 1982;13:73–9.
Walsh JB . Hypertensive retinopathy: description, classification and prognosis. Ophthalmology 1982;89:1127–31.
Ahmed MEK, Walker JM, Beevers DG, Beevers M . Lack of difference between malignant and accelerated hypertension. BMJ 1986;292:235–7.
McGregor E, Isles CG, Jay JL, Lever AF, Murray GD . Retinal changes in malignant hypertension. BMJ 1986;292:233–4.
World Health Organization. Arterial hypertension. WHO Tech Rep Ser 1978;628:57.
Eames SM, Beevers DG, Dodson PM . Hypertension and the retina. In: Dodson PM, Gibson JM, Kritzinger EE, editors. Clinical retinopathies. London: Chapman Hall, 1995.
Breckenbridge A, Dollery CT, Parry EHO . Prognosis of treated hypertension: changes in life expectancy and cause of death between 1952 and 1967. Q J Med 1970;39:411–29.
Gudbransson T, Hansson L, Herlitz H, Andren L . Malignant hypertension: improving prognosis in a rare disease. Acta Med Scand 1979;206:495–9.
Lowenstein J . The effects of treatment on target organ damage in hypertensive disease. Postgrad Med J 1985;61:773–8.
Bock KD . Regression of retinal vascular changes by antihypertensive therapy. Hypertension 1984;6:158–62.
Tso MOM, Jampol LM . Pathophysiology of hypertensive retinopathy. Ophthalmology 1982;89:1132–45.
Tso MOM, Jampol LM . Hypertensive retinopathy, choroidopathy and optic neuropathy of hypertensive disease. In: Laragh JH, Brenner BM, editors. Hypertension: pathophysiology, diagnosis and management. New York: Raven Press, 1990:433–65.
Hayreh SS, Servais GE, Virdi PS, Marcus ML, Rojas P, Woolson RF . Fundus lesions in malignant hypertension. III. Arterial blood pressure, biochemical and fundus changes. Ophthalmology 1986;93:45–59.
Hayreh SS, Servais GE, Virdi PS . Fundus lesions in malignant hypertension. V. Hypertensive optic neuropathy. Ophthalmology 1986;93:74–87.
Thompson PD, Mastaglia FL, Carroll WM . Anterior ischaemic optic neuropathy: a correlative clinical and visual evoked potential study of 18 patients. 1986;49:128–35.
Fastenberg DM, Fetkenhour CL, Choromokos E, Shoch DE . Choroidal vascular changes in toxemia of pregnancy. Am J Ophthalmol 1980;89:362–8.
Carr RE, Siegel IM . Electrodiagnostic testing of the visual system: a clinical guide. Philadelphia: FA Davis, 1990.
Garner A, Ashton N . Pathogenesis of hypertensive retinopathy: a review. J R Soc Med 1979;72:362–5.
Talks SJ, Chong NHV, Gibson JM, Dodson PM . Fibrinogen, cholesterol and smoking as risk factors for non-arteritic anterior ischaemic optic neuropathy. Eye 1995;9:85–8.
Guyer DR, Miller NR, Auer CL, Fine SL . The risk of cerebrovascular and cardiovascular disease in patients with anterior ischaemic optic neuropathy. Arch Ophthalmol 1985;103:1136–42.
Smith JL, Goldhammer Y . Hypertensive optic neuropathy. Trans Am Acad Ophthalmol Otolaryngol 1974;79:520–3.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Talks, S., Good, P., Clough, C. et al. The acute and long-term ocular effects of accelerated hypertension: A clinical and electrophysiological study. Eye 10, 321–327 (1996). https://doi.org/10.1038/eye.1996.67
Issue Date:
DOI: https://doi.org/10.1038/eye.1996.67
Keywords
This article is cited by
-
The Effect of Magnesium on Visual Evoked Potentials in L-NAME-Induced Hypertensive Rats
Biological Trace Element Research (2016)
-
Hypertension and the eye: changing perspectives
Journal of Human Hypertension (2002)
-
Hypertensive crises
Current Treatment Options in Cardiovascular Medicine (1999)
-
Reversible anterior ischaemic optic neuropathy in accelerated hypertension
Eye (1998)